SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (10753)3/1/2004 8:10:44 PM
From: tuck  Respond to of 52153
 
Contributors to JCO attempt to relate oncology drug pricing to remaining patent life or market size. No dice, but worth reading:

jco.org

Bexxar, Zevalin, and Campath are very expensive. Which may explain Corixa being dead in the water since approval. If memory serves, it was only a marginal improvement over competing drugs such as Rituxan.

Cheers, Tuck